Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

259.93
-1.6600-0.63%
Post-market: 260.460.5300+0.20%19:54 EDT
Volume:3.89M
Turnover:1.01B
Market Cap:459.40B
PE:73.43
High:262.32
Open:260.51
Low:259.00
Close:261.59
52wk High:269.39
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.03
T/O Rate:0.22%
Dividend:6.83
Dividend Rate:2.63%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-77.40
PE(LYR):110.14

Loading ...

AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable Nov. 16 to Holders of Record Oct. 15

MT Newswires Live
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS
·
Sep 09

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS
·
Sep 09

Movement Alert|AbbVie Falls 3.13% in Regular Trading, Trading at $248.79

Market Focus
·
Sep 09

Headlands Research Names Brandon Pallott Chief Commercial Officer

Reuters
·
Sep 09

BofA Securities Adjusts Price Target on AbbVie to $282 From $276

MT Newswires Live
·
Sep 08

AbbVie price target raised to $282 from $276 at BofA

TIPRANKS
·
Sep 08

Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.

Dow Jones
·
Sep 08

Abbvie : Bofa Global Research Raises Price Objective to $282.00 from $276.00

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08